Recursion Pharmaceuticals (RXRX) Non-Current Debt (2020 - 2026)

Recursion Pharmaceuticals has reported Non-Current Debt for 7 years, with the latest figure at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 56.34% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (down 56.34% YoY), and the FY2025 full-year result was $9.6 million, down 49.72% from the prior year.
• Non-Current Debt for Q1 2026 stood at $7.2 million, down from $9.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $22.9 million in Q2 2024, with the low at $536000.0 in Q4 2022.
• Historically, Non-Current Debt has averaged $7.6 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Debt plunged 94.1% — and 2024, when it surged 1884.5%.
• Recursion Pharmaceuticals' Non-Current Debt stood at $536000.0 in 2022, then surged by 105.41% to $1.1 million in 2023, then jumped by 1627.7% to $19.0 million in 2024, then sank by 49.72% to $9.6 million in 2025, then declined by 24.92% to $7.2 million in 2026.
• The last three Non-Current Debt figures came in at $7.2 million (Q1 2026), $9.6 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.